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Summary
It is paramount that any child or adolescent with a suspected disor-
der of sex development (DSD) is assessed by an experienced clini-
cian with adequate knowledge about the range of conditions
associated with DSD. If there is any doubt, the case should be dis-
cussed with the regional team. In most cases, particularly in the case
of the newborn, the paediatric endocrinologist within the regional
DSD team acts as the first point of contact. The underlying patho-
physiology of DSD and the strengths and weaknesses of the tests that
can be performed should be discussed with the parents and affected
young person and tests undertaken in a timely fashion. This clinician
should be part of a multidisciplinary team experienced in manage-
ment of DSD and should ensure that the affected person and parents
are as fully informed as possible and have access to specialist psycho-
logical support. Finally, in the field of rare conditions, it is impera-
tive that the clinician shares the experience with others through
national and international clinical and research collaboration.
(Received 8 February 2011; returned for revision 6 March 2011;
finally revised 6 April 2011; accepted 12 April 2011)
Introduction and development of guidance
Disorders of sex development (DSD) are a wide range of conditions
with diverse pathophysiology1 that most often present in the
newborn or the adolescent. Affected newborns usually present with
atypical genitalia whereas adolescents present with atypical sexual
development during the pubertal years. These clinical situations can
often be difficult to manage, particularly in those cases where the
sex of rearing is uncertain. Establishing a dialogue and building rap-
port with the affected child and the parents, evaluating the child and
then developing a logical, as well as pragmatic, plan for investiga-
tions are central to the initial approach and ongoing management.
The consensus that was reached in Chicago in 2005 on the
general principles of managing patients with DSD represented a
historic milestone for international and multidisciplinary collabo-
ration in this area.2,3 Some areas of care such as the initial approach
to evaluating the infant or young person with suspected DSD were
not covered in detail as that was beyond the scope of the exercise.
Guidance on the initial evaluation of a complex condition is often
coloured by local provision of health care, and it was felt that reach-
ing a consensus at a national, United Kingdom, level may be the
most effective means of proceeding further. A UK DSD taskforce
was formed in March 2009 under the auspices of the Society for
Endocrinology, and it was agreed that the remit of this group
would be to concentrate on guidance on the initial evaluation pro-
cess and the diagnostic approach rather than the clinical manage-
ment of the condition once a provisional or definitive diagnosis has
been reached. This guidance would be aimed at a range of clinical
professionals who encounter newborns and adolescents with DSD
and its purpose would not be to simply act as a manual but to har-
monize good clinical practice. Stakeholder professional societies
and clinical professionals who could represent these societies were
identified and approached to join the group as were members of
two patient representative groups. These group members took
responsibility for individual sections and based their opinion on
observational studies and expert opinion and the whole group con-
sidered each draft. After completion, the guidelines were subject to
open external review by the involved professional societies and
their members as well as patient group representatives. After this
period of open consultation of over 3 months, comments were
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reviewed and most suggestions were incorporated. All members of
the group have approved the final draft of the guidance.
Themultidisciplinary team
Optimal care for infants and adolescents with DSD requires an
experienced multidisciplinary team (MDT) that should be accessi-
ble through regional centres. The team may exist as a clinical net-
work with links between more than one specialist centre. As a
minimum standard, the clinical team should include specialists in
endocrinology, surgery and/or urology, clinical psychology/psychi-
atry, radiology, nursing and neonatology. For infants with sus-
pected DSD, this team should develop a plan for clinical
management with respect to diagnosis, sex assignment and treat-
ment options before making any recommendations to the parents.
In addition, the clinical team should have links to a wider MDT
that consists of specialists from adult endocrinology, plastic sur-
gery, gynaecology, clinical genetics, clinical biochemistry, adult
clinical psychology, social work and, if possible, to a clinical ethics
forum (Table 1).4 Ideally, discussions with the family are lead by
one professional, and in most situations, particularly in the case of
the newborn, the endocrinologist assumes the role of clinical lead
and oversees the timely involvement of other members of the team.
However, the core composition of the team for each affected per-
son and family will vary according to DSD type, family need or par-
ent preference, local resources, developmental context and location
as well as the age of the person. The parents and the young person
should be informed of the range of help that is available from the
MDT and should be provided with contact details of these person-
nel. Ongoing communication with the family’s primary care physi-
cian is important, and consent issues in relation to sharing
information outside of the hospital setting should be discussed
with parents and young person. The team has a responsibility to
educate other healthcare staff and should have a forum to meet reg-
ularly, in the context of a clinic and an educational meeting where
it can review and discuss its own performance. Audit of clinical
activity, research studies, building collaborative working partner-
ships with other DSD teams and attendance at joint clinics and
education events are crucial if knowledge and information sharing
is to be optimized across MDT teams. Transfer of care for the ado-
lescent should be organized with the MDT operating in an environ-
ment comprising specialists with experience in adolescent care.5
Psychological support for the affected person and
family
Early psychological input, provided by a specialist clinical psychol-
ogist with experience of supporting people with DSD and their par-
ents, will allow the latter to examine and understand their early
emotional reactions as well as explore present and future worries,
adjust to the period of uncertainty during the diagnosis process
and facilitate inclusion in informed decision making about them-
selves or their child.6,7 The clinical psychologist is also well placed
to assess how well the family is coping and functioning, assess and
facilitate the bonding of the parents with the infant, and, in the case
of the young person, perform an assessment of gender identity,
Table 1. The clinical members of the MDT and their roles in providing
care to the patient and the parents. Professionals marked with an asterisk
are core members of the MDT who should meet regularly to discuss cases in
a clinic setting
Role
Neonatologist or General Paediatrician
Initial explanation
Management of the unwell child
Initiation of first-line investigations
Seek advice from paediatric subspecialist (endocrine or surgical)
with an interest in DSD
Paediatric Endocrinologist*
Detailed explanation over multiple visits
Management of the unwell child
Interpreting first-line investigations and planning second-line
investigations
Organize timely and appropriate involvement of other members of MDT
Act as the link between the parents and MDT
Initiate and monitor long-term medical therapy such as steroid or sex
steroid therapy
Paediatric Radiologist
Interpret and often perform ultrasound scans in the newborn
Judge the reliability of ultrasound scans in the newborn especially
when the results may influence sex assignment
Assessment of external anatomy
Paediatric Urologist*
Explanation of the anatomy and results of imaging
Explanation of pros and cons of reconstructive surgery
Develop a plan for complex imaging (other than pelvic ultrasound)
and further assessment of the anatomy
Perform procedures such as laparoscopy, biopsy, reconstructive
surgery and gonadectomy
Organize timely and appropriate involvement of other members of
MDT
Paediatric Specialist Nurse*
Provide general support to the patient and parents in addition to
that provided by other members of the MDT
Arrange specialist investigations
Liaise with the rest of the DSD team, especially the clinical psychologist
Clinical Psychologist*
Provide specialist support to parents soon after birth
Provide support to the growing child and the parents
Develop an individualized plan for each family
Guide the MDT on timing and tempo of explanation of the condition
to the older child and adolescent
Clinical Endocrine Biochemist*
Facilitate timely analysis of samples
Provide specialist support and interpretation of results
Guide subsequent biochemical tests
Facilitate storage of samples for analysis at a later stage
Clinical Geneticist*
Facilitate timely analysis of karyotype
Closer involvement in the child with dysmorphic features
Oversee the process of genetic analysis
Facilitate storage of samples for analysis at a later stage
Genetic counselling
Gynaecologist*
Availability at an early stage to discuss future outcome
Discuss issues related to sexual function, reproductive function and
surgery
Assess the understanding and review the diagnosis
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when appropriate. As a minimum, the parents of every newborn
with suspected DSD where there has been a delay in sex assignment
should be offered clinical psychology input. In addition, all
adolescents with a newly diagnosed DSD or existing DSD requiring
medical or surgical attention should be routinely offered clinical
psychology input in addition to any support offered to their par-
ents or wider family. The point of transfer from paediatric to adult
services offers an ideal opportunity for a routine assessment of the
need for clinical psychology input.
Discussions with parents and young people need to occur on
multiple occasions in a quiet and peaceful setting, with enough
time for the family and MDT to develop a shared understanding of
investigations, results, diagnosis, treatments and the value of ongo-
ing psychological support for both themselves and/or their child.
The pace of how information is shared should be set by the family,
and issues of confidentiality discussed and respected.8 Parents’ and
young people’s initial recollections of conversations with profes-
sionals may have a long-lasting effect on them and their relation-
ship with their affected child and health professionals.9 The use of
phrases such as ‘differences’ or ‘variations’ in sex development may
help to introduce the concept of the range of variation that may
occur in sex development. A record of early discussions, either as
audiotapes or a letter, which is shared between the parents and
other immediate members of the MDT and the general practitioner
may be helpful. Use of drawings and written material during dis-
cussion and a list of websites and support groups are useful aids for
families.
Parents and young people need to be aware that the management
of the condition will require a stepwise approach that first targets
short-term goals and then long-term goals that achieve optimal
long-term well-being. It is very likely that families’ decisions will be
shaped by their own expectations, experiences and their under-
standing of sex and gender roles within the religious and cultural
context of their own social networks. The MDT should also be
aware of how their own values and beliefs are played out in consul-
tation with the family. Some parents may consider early genital sur-
gery as a mechanism that could possibly protect their child from
the risk of future stigma. This will require a thorough discussion
with several members of the MDT team including the clinical psy-
chologist, surgeons, gynaecologist and nurses so that the parents
are fully informed around the controversies around undertaking or
withholding early genital surgery.10 Parents and young people will
need support and guidance about how to share news following the
birth of their child/diagnosis and manage the social challenges they
may face at this time.8,11
The role of the support group
Support groups can provide ongoing support to parents and the
affected individual, including opportunities to gather and explore
information, promote autonomy and build knowledge and self-
confidence regarding the diagnosis of DSD. For parents, gathering,
using and questioning information will shape their understanding
as they often act as the advocate for their child or young person and
therefore need to be fully informed about DSD practice, short- and
long-term outcomes of treatments and health risks and psychologi-
cal challenges for their child. Support groups can provide a range
of such information via websites and newsletters as well as through
phone helplines and group meetings for both families and profes-
sionals.9 They can also work in collaboration with the MDT to help
families as well as affected people in seeking appropriate medical
care and improve patients’ understanding of their condition as well
as the reasons for medical therapy.6 Alongside the formal psycho-
logical support provided by the specialist clinical psychologist, sup-
port groups can also offer invaluable peer support to families and
individuals affected by DSD. By being in touch with others with a
similar condition and belonging to a support group, people can
gain a sense of empowerment and the whole experience may also
normalize a condition which may have previously been perceived
as a source of stigma and shame.12 Healthcare professionals rely on
support groups for guidance on the development of healthcare
strategy as well as for providing the opportunity to interact with
affected people at national support group meetings and confer-
ences.13 Contact details of support groups should be supplied as
routine as part of any written information. It is possible that fami-
lies may prefer to talk to other local families affected in a similar
way and regional services should attempt to create a local pool of
helpers and explore locally organized support and education days.
Which newborn should be investigated and how
extensively?
If the appearance of the external genitalia is sufficiently ambiguous
to render sex assignment impossible or the phenotype is not consis-
tent with prenatal genetic tests, then de facto, extensive investiga-
tion is required. However, the extent of genital ambiguity may
depend on the expertise of the observer, and prior to presentation
to a clinical expert, the label of ambiguous genitalia is often
assigned to newborns where the most appropriate sex of rearing is
not immediately clear to those present at the child’s birth. The birth
prevalence of genital anomalies may be as high as one in 300
births14 but the birth prevalence of complex anomalies that may
lead to true genital ambiguity on expert examination may be as low
as one in 5000 births.15
Besides those whose genitalia are truly ambiguous, in the clinical
situation, infants can often be divided into those who are
Table 1. (Continued)
Role
Assess the need for psychology support in the adolescent girl
Initiate and monitor long-term sex steroid therapy
Adult Endocrinologist
Investigate and manage the adolescent presenting for the first time after
the age of 16 years
Liaise with other members of the MDT
Act as the link between the patient and MDT
Initiate and monitor long-term medical therapy such as steroid or sex ste-
roid therapy
Act as the transition link for adolescents under paediatric care
MDT, multidisciplinary team.
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apparently a boy with atypical genitalia and those who are appar-
ently a girl with atypical genitalia. However, it is very important to
bear in mind that the same girl with congenital adrenal hyperplasia
(CAH) may present as an apparent girl with clitoromegaly or an
apparent boy with bilateral undescended testes. When evaluating
these infants, the clinical features of the external genitalia that
require examination include the presence of gonads in the labioscr-
otal folds, the fusion of the labioscrotal folds, the size of the phallus
and the site of the urinary meatus on the phallus, although the real
site of the urinary meatus may, sometimes, only become clear on
surgical exploration.16 These external features can be individually
scored to provide an aggregate score, the external masculinization
score (EMS; Fig. 1).17 Routine systematic examination of 423 con-
secutive, apparently healthy, term newborn boys revealed that 412
(98%) had the maximum EMS of 12, 10 had an EMS of 11 and only
1 of 423 had an EMS of <11.17 In boys with genital anomalies, a
chromosomal anomaly may be present in approximately 3% of
those with isolated cryptorchidism, 7% of those with hypospadias
and 13% of those with a combination of cryptorchidism and hypo-
spadias.18 In infants with proximal hypospadias (penoscrotal, scro-
tal, perineal), detailed biochemical and molecular studies
performed a decade ago revealed a likely cause in 31% of cases.19
With advances in biochemical and molecular techniques, it is
unclear whether the diagnostic yield is even greater now.
Infants with suspected DSD who require further clinical evalua-
tion and need to be considered for investigation by a specialist
should include those with isolated perineal hypospadias, isolated
micropenis, isolated clitoromegaly, any form of familial hypospa-
dias and those who have a combination of genital anomalies with
an EMS of <11. This will avoid unnecessary detailed investigations
into boys with isolated glandular or mid-shaft hypospadias and
boys with unilateral inguinal testis. The co-existence of a systemic
metabolic disorder, associated malformations or dysmorphic fea-
tures would lower the threshold for investigation as would a family
history of consanguinity, stillbirths, multiple miscarriages, fertility
problems, genital abnormalities, hernias, delayed puberty, genital
surgery, unexplained deaths and the need for steroid replacement.
In addition, maternal health and drug exposure during pregnancy
and the pregnancy history itself may hold key information.
In all infants with ambiguous genitalia and/or bilateral impalpa-
ble gonads, a first tier of investigations should be undertaken to
define the sex chromosomes and delineate, by pelvic ultrasound,
the internal genitalia and exclude life-threatening CAH – the com-
monest cause of ambiguous genitalia of the newborn. This first tier
should, therefore, also include plasma glucose, serum 17OH-pro-
gesterone (17OHP) and serum electrolytes. Serum 17OHP is usu-
ally unreliable before the age of 36 h, and in the salt-losing form of
CAH, serum electrolytes usually do not become abnormal before
day 4 of life. The results of PCR or FISH analysis using Y and
X-specific markers should be available within one working day and
the 17OHP results should be available with a maximum of two
working days in all specialist DSD centres. In situations where the
level of suspicion of CAH is very high and the infant needs immedi-
ate steroid replacement therapy, further serum samples should be
collected and stored before starting therapy. These should be of a
sufficient volume to assess 17OHP, testosterone, androstenedione
and, possibly, renin activity or concentration, in that order of pri-
ority. At least one spot or 24-h urine sample (at least 5 ml) for a
urine steroid profile should be collected before starting therapy.
The results of these initial investigations shall often dictate the sec-
ond tier of investigations.
In an infant with impalpable gonads, a karyotype of 46,XX, a sig-
nificantly elevated serum 17OHP and the presence of a uterus make
CAH because of 21-hydroxylase deficiency very likely. A urine ste-
roid profile can confirm this diagnosis and can also identify other
rare forms of CAH that may also be associated with a raised
17OHP in the newborn. In infants with sex chromosomes other
than 46,XX, a second tier of investigations is necessary to determine
the presence of testes and the adequacy of androgen production
and action. These tests include measurement of serum anti-Mu¨lle-
rian hormone (AMH), the human chorionic gonadotrophin
(hCG) stimulation test, further detailed imaging and laparoscopy.
Confirmation of a specific diagnosis will often require further bio-
chemical identification of a defect in the androgen biosynthesis
pathway and detailed genetic analysis.
Which adolescent should be investigated and how
extensively?
The initial assessment in an affected adolescent should be aimed at
establishing a relationship with the patient and starting the process
of diagnosis. In adolescents with an existing DSD, transferring to
adult services is an opportunity to review the diagnosis and con-
sider further investigations. An appropriate hospital setting is very
important for the sensitive management of complex conditions
with full access to the necessary medical, nursing and psychological
care. Whilst the explanation of the diagnosis to the patient and the
family is critical, this needs to be performed sensitively and care-
fully and expert psychological input is essential.
Adolescents may typically present with a suspected DSD in three
ways – a girl with primary amenorrhoea (with or without breast
development), a girl who virilizes at puberty or a boy with pubertal
delay (Fig. 2). The potential psychological impact of examinations
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Fig. 1 Calculating the External Masculinisation Score provides an objective
aggregate score of the extent of masculinization of the external genitalia.
Each individual feature of the genitalia (phallus size, labioscrotal fusion, site
of the gonads and location of urethral meatus) can be individually scored to
provide a score out of 12. 1Microphallus refers to a phallus below the male
reference range. 2L/S, labioscrotal; Ing, inguinal; Ab, abdominal or absent
on examination.
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and medical photography should be considered, and for the adoles-
cent, a thorough physical examination by a surgeon and a
gynaecologist, depending on the sex of the adolescent, may only be
appropriate under an anaesthetic.20
In girls with primary amenorrhoea, investigations should be con-
sidered at the age of 14 years if there is no pubertal development
and at 16 years if other aspects of puberty, particularly breast devel-
opment, have progressed normally. History should include a family
history and an assessment of co-existing chronic disease, exercise
and weight changes. Physical examination should include measure-
ment of blood pressure, height and weight and assessment of sec-
ondary sexual characteristics including clitoral enlargement.
Vaginal examination to assess vaginal length is rarely indicated
when imaging is informative and should be clearly explained and
performed by a gynaecologist. An initial investigation screen should
comprise measurements of serum electrolytes, LH, FSH, prolactin,
TSH, FT4, sex hormone binding globulin (SHBG), androstenedi-
one, oestradiol, testosterone and transabdominal pelvic ultrasound
by sonographer who has experience of adolescent appearances.
Raised gonadotrophins or an absent uterus in the presence of nor-
mal breast development are indications for a karyotype.
The appearance of clitoromegaly and hirsutism at puberty in the
presence of primary amenorrhoea is a classical presentation of two
46,XY DSDs: 17b-hydroxysteroid dehydrogenase type 3
(17bHSD3) deficiency and 5a-reductase type 2 deficiency. It is less
typical of partial androgen insensitivity syndrome (PAIS) which is
usually associated with ambiguous genitalia at birth. In all these
conditions, Mu¨llerian structures will not be detectable. Also, in
partial gonadal dysgenesis and ovotesticular DSD, the mild clitoro-
megaly that may have been present at birth may have been over-
looked but becomes a more prominent feature at adolescence. The
differential diagnosis would also include CAH and androgen-
secreting tumours of the ovary or adrenal gland; in all these cases,
Mu¨llerian structures are present. Investigations include serum
measurements of LH, FSH, dehydroepiandrosterone (DHEAS),
SHBG, androstenedione, testosterone, dihydrotestosterone (DHT)
and 17OHP. A 24-h urine collection for urinary steroid profile
(USP) will confirm 5a-reductase type 2 deficiency, CAH or adreno-
cortical tumour. A pelvic ultrasound will assess the presence of a
uterus and determine the need for a karyotype.
Although the commonest cause of delayed puberty is constitu-
tional delay, all boys with delayed puberty who are over the age of
14 years should be assessed. Overweight boys need careful exami-
nation so that a buried penis is not mistaken for micropenis.
Rarely, PAIS, a disorder of testosterone biosynthesis or mild forms
of testicular dysgenesis, can present in this age group, especially if
there is a history of hypospadias repair or orchidopexy. Investiga-
tions include a bone age and serum measurements of LH, FSH, tes-
tosterone and prolactin. For those with raised gonadotrophins,
karyotype should be performed to exclude disorders such as Kline-
felter’s syndrome (47,XXY and variants) or 45,X/46,XY mosaicism.
The role of the clinical geneticist
Establishing a specific molecular diagnosis is helpful in clinical
management of cases and in offering accurate genetic counselling
for the family. However, the number of diagnostic gene tests that
are available in accredited DNA laboratories in the United King-
dom or internationally is limited and costly. As recent develop-
ments in DNA and chromosomal analysis accelerate biomedical
research, many techniques such as multiplex ligation-dependent
probe amplification (MLPA) and comparative genomic hybridiza-
tion (CGH) have the potential to become routine in clinical
practice. Next-generation DNA sequencing platforms will allow
whole-genome sequencing for rare diseases to become a reality at a
realistic price.21,22 The clinical geneticist at the specialist DSD cen-
tre is correctly placed to evaluate complex genetic syndromes and
also judge which technique is appropriate and cost-effective for
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Fig. 2 Approach to investigating adolescent girls
with primary amenorrhoea.
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each clinical situation. DNA can be stored indefinitely with
consent, so when further diagnostic testing opportunities arise,
aliquots of DNA can be accessed, avoiding repeated venepuncture.
If a molecular diagnosis is reached in a research laboratory, then
confirmation of this result in an accredited laboratory should be
sought where possible, before disclosing results to the family. Close
involvement of the clinical genetics service can ensure that the
MDT covers all aspects of genetic counselling including provision
of information to the family, the mode of inheritance of the disor-
der and the choices or options available for dealing with this risk.
Established links with the clinical genetics service are also useful
when considering prenatal testing or interventions such as steroid
therapy in CAH (Fig. 3).
Assessment of anatomy
Examination and assessment by a paediatric surgeon with
experience of DSD is critically important in the affected newborn.
Combining expert physical examination with endoscopic visualiza-
tion and radiological assessment can provide information on the
location and state of the gonads, the urogenital sinus and Mu¨llerian
structures. During this initial assessment, the anatomy and drain-
age of the renal tract should also be assessed.23,24
Ultrasonography is the first-line imaging modality and should
include the adrenals, kidneys, pelvis, inguinal regions and scrotum
where appropriate. In the neonate, the uterus, ovaries and adrenals
should be identifiable but the reliability is child and operator
dependent. It should also be borne in mind that the presence of a
uterine structure does not guarantee later function, and intra-
abdominal testes and streak gonads are difficult to identify ultraso-
nography. In the adolescent, it is sometimes difficult to confirm the
presence of a prepubertal uterus by ultrasonography and there may
be a place for repeat imaging after a 6-month course of oestrogen.
Magnetic resonance imaging (MRI) should be reserved for cases
where ultrasonography has failed to delineate the relationship of
the Mu¨llerian structures and where there are abnormalities of the
urinary tract. High-resolution MRI should include the pelvis and
perineum, using high-resolution T2 with and without fat
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saturation and T1 in three planes where possible. MRI can identify
extra-abdominal ectopic testes and the presence of the spermatic
cords, but is of less value in trying to define the presence and char-
acter of intra-abdominal testes or streak gonads. In adolescents,
MRI can delineate structural anomalies such as hydrometrocolpos
or hydronephrosis and identify secretory tumours. In general, T1
imaging of the upper abdomen in adolescents is not required unless
there is an adrenal mass in which case contrast enhancement shall
also be required.25,26
Nowadays, the ‘genitogram’ is not routinely performed for diag-
nostic purposes. It has been superseded by endoscopic examination
of the genital tract (genitoscopy), which provides a more detailed
and thorough assessment. However, at the time of surgery, stents
can be accurately placed in various structures to allow a more
focused radiological examination. These investigations need to
provide information on the length of the urogenital sinus, the asso-
ciated Mu¨llerian structures and the relationship of the urethra and
its sphincter. In 46,XX DSD, genitoscopy can assess the need for
drainage of both the bladder and Mu¨llerian structures and provide
a detailed assessment of the urogenital anatomy. In 46,XY DSD,
endoscopic examination can be used to identify any Mu¨llerian
remnants that arise from the posterior urethra.
Genitoscopy can be augmented by laparoscopy, but this is not
necessary in all cases of DSD. It is a very effective method of visual-
izing the internal sex organs and facilitates direct inspection, biopsy
or excision of intra-abdominal gonads. However, as laparoscopy
can only visualize intraperitoneal structures, Mu¨llerian remnants
deep within the pelvis or closely attached to the bladder may not be
seen. In 46,XY DSD, laparoscopy is clearly indicated in all infants
with impalpable testes where the gonads need to be identified and
brought down to the scrotum if possible. Laparoscopy can also be
used in adolescents who present with a DSD. However, MRI may
be a more suitable first-line investigation for defining the anatomy.
Steroid measurement and its interpretation
Steroid hormone analysis is a vital component of the biochemical
evaluation but the method of analysis can have a significant impact
on the result.27 Analysis is most often performed by nonextraction,
nonchromatographic (direct) immunoassays on automated plat-
forms and these are subject to concerns of analytical specificity.28,29
Liquid chromatography linked with tandem mass spectrometry
(LC-MS/MS) allows multiple analyte analysis from a single sample
whilst maintaining analytical specificity.30 Thus, in cases of DSD,
plasma or serum steroids should be measured by either LC-MS/MS
or immunoassays after organic solvent extraction. As these are
more labour intensive, there may be an impact on the turnaround
time for results and on clinical decision making. Close communica-
tion between the clinical and biochemistry personnel within the
DSD team is vital to enable correct interpretation of laboratory
results and awareness that results should be available in a timely
manner.
Urinary steroid profile analysis by gas chromatography mass
spectrometry (GC-MS) provides qualitative and quantitative data
on excretion of steroid metabolites. It is ideal for detecting altered
steroid metabolites, especially in cases of CAH where the activity of
a combination of steroidogenic enzymes can produce unusual
metabolites that can cross-react in traditional serum assays.31 The
diagnosis of rarer forms of CAH such as P450 oxidoreductase defi-
ciency (ORD) is best established using urinary GC-MS analysis as it
allows for concurrent determination of all adrenal-derived steroid
metabolites.32 As gonadotrophins, androgens and precursors, fluc-
tuate markedly over the first few months of life and may lead to a
diagnostically blind window, there is a place to consider an early
neonatal collection as well as further samples at a later stage. A
urine sample can be frozen and stored for many years and may help
with a review of the diagnosis at a later stage. USP is not appropri-
ate for suspected cases of 5a-reductase type 2 deficiency until after
3 months of age as diagnostic pairs of 5b to 5a reduced metabolites
are not detectable until then.
Normally, infants, particularly boys, have significant changes in
steroid and other endocrine hormone concentrations during the
first 100 days of birth.28,33 In boys, serum testosterone and DHT
may initially be high at birth but decline to <1 nmol/l or undetect-
able, respectively. Concentrations then rise from around day 30
after birth to peak at day 70 before declining to normal prepubertal
concentrations.33 These normal variations may influence the inter-
pretation of sex steroid and gonadotrophin measurements as well
as the results of the hCG stimulation test. Furthermore, the actual
value for the hormone concentration will vary depending on the
assay methodology.
SerumAnti-Mu¨llerian hormone
Anti-Mu¨llerian hormone, also known as Mu¨llerian-inhibiting sub-
stance (MIS), is strongly expressed in Sertoli cells from the time of
testicular differentiation to puberty and to a much lesser degree in
granulosa cells from birth to menopause and is widely used nowa-
days to assess ovarian reserve.34 Published information on circulat-
ing AMH concentrations have to be interpreted with caution
because of differences in the way immunoassays are standardized
and the units used for measurement. It is, therefore, important to
liaise with the specialist clinical biochemist to ensure appropriate
reference ranges are used for interpretation. In boys, AMH is
detectable at birth at much higher circulating concentrations than
in girls and these concentrations rise over infancy before gradually
declining at puberty. Therefore, up to date, age-, sex- and method-
related reference ranges are necessary for interpretation.35 In male
neonates, levels that are close to the lower end of the normal range
should be repeated later in infancy as they should rise further in
boys with normal testes. As summarized in Table 2, measurement
of AMH is a powerful tool to assess Sertoli cell activity in children
with suspected DSD and may also have a diagnostic utility in con-
ditions associated with androgen deficiency or insensitivity
(Table 2).36
The human chorionic gonadotrophin stimulation test
Stimulation with hCG allows the identification of functioning tes-
ticular tissue as well as biosynthetic defects in testosterone synthesis
(Fig. 4). However, it is an invasive test that should only be
performed as a second-line investigation after discussion with the
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paediatric endocrinologist in the regional DSD team. Most proto-
cols for hCG stimulation in the United Kingdom use intramuscular
hCG 1000–1500 units on three consecutive days.37 This can be
followed by further hCG stimulation with 1500 units on 2 days a
week for the following 2 weeks. In young infants and adolescents,
3 days of hCG stimulation may be sufficient,38 and in the very
young infant with an intrinsically active gonadal axis, an hCG stim-
ulation test may not be necessary if serial blood samples show
raised serum testosterone concentrations. A testosterone response
to hCG may be labelled as normal if absolute testosterone concen-
trations reach a level that is above the upper limit of the normal
prepubertal range or rise by more than twice the baseline value. As
a minimum, other androgens that should be assessed include DHT
and androstenedione. For these two metabolites, the post-hCG,
day 4 sample is more important than the pre-hCG, day 1 sample
and there does not seem to be any additional benefit of analysing a
sample for these two metabolites on day 22, following prolonged
hCG stimulation, if there are sufficient samples to analyse on day
4.38 The day 22 sample that is collected for testosterone measure-
ment should be stored and can be used to measure DHT or andro-
stenedione if a sufficient sample was not available at day 4.
In routine cases of XY DSD, a persistently low AMH may have a
high predictive value for a low hCG-stimulated testosterone con-
centration but a normal AMH has a low predictive value for a nor-
mal hCG-stimulated testosterone value.35 These relationships
between the two variables do not apply to cases of persistent Mu¨lle-
rian duct syndrome where there is an intrinsic defect of AMH or
the AMH receptor. There is no evidence that a urine steroid profile
or a serum AMH checked after hCG stimulation has any added
diagnostic value. In the presence of a poor testosterone response
following hCG stimulation, assessment of adrenal function by a
standard short synacthen stimulation test should be considered in
Table 2. Interpretation of serum AMH concentration in DSD
Serum AMH
Testicular
tissue Interpretation
Undetectable Absent 46,XX CAH
Complete gonadal dysgenesis
PMDS due to AMH gene defect
Within female
age-related
reference range
Usually
absent
46,XX CAH
Dysgenetic testes or ovotestes
Below male or
above female
age-related
reference range
Present Dysgenic testes
Ovotestes
Within male
age-related
reference range
Usually
normal
Nonspecific XY DSD
Hypogonadotrophic hypogonadism
PMDS due to AMH-R defect
46,XX testicular DSD
Ovotestes
Above male
age-related
reference range
Present AIS especially complete androgen
insensitivity syndrome
5a-reductase deficiency
Testosterone biosynthetic defect
Leydig cell hypoplasia
AMH, anti-Mu¨llerian hormone; CAH, congenital adrenal hyperplasia;
DSD, Disorders of sex development.
Low T and 
low precursors
Low T and 
high precursors
High T, low DHT
high Ur 5β:5α
High/normal/low T
normal DHT
normal/high AMH
Poor functional response to T
LHR 
Gon dysg
SF-1
StAR
P450scc
SF-1
CYP17A1
POR
HSD3B2
SRD5A2 AR
Standard HCG stimulation
ACTH stimulated cortisol response2
CYP17A1 def
POR def
HSD3B2 def
HSD17B3 def
Prolonged HCG 
stimulation1
Low T and 
low precursors
Normal Low Normal Low
HSD17B3 
Fig. 4 Interpretation of the results of the human chorionic gonadotrophin (hCG) stimulation test when investigating XY DSD and pointers for consideration
of prolonged hCG stimulation and adrenocorticotrophin hormone stimulation. 1Prolonged hCG stimulation test should be considered in those cases where
there is a poor testosterone (T) response to a standard hCG stimulation test. 2Synacthen stimulation test should be considered in those cases who show a poor
testosterone response to hCG stimulation. 46,XY children with lipoid congenital adrenal hyperplasia due to a steroidogenic acute regulatory defect or P450scc
deficiency due to CYP11A1 defect will have female genitalia and present in a salt-losing state in the first days or weeks of life before synacthen performed.
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all cases. There is less experience as well as a lower demand for a
corresponding test to assess ovarian tissue but recent reports of
ovarian hormones following stimulation with FSH need to be
explored further.39,40 There is currently insufficient evidence to rec-
ommend that everybody with XY DSD should have a synacthen
stimulation test but clinicians should be aware of the clear associa-
tion between some forms of DSD and primary adrenal insufficiency
and should consider thorough assessment of adrenal function in
those diagnoses where an association has already been described
and in those with any clinical suspicion of adrenal insufficiency,
especially those with low steroid precursors on USP.
XX DSD
46,XX DSD can be classified into disorders of ovarian development,
conditions with androgen excess and other syndromes, which are
often associated with other developmental abnormalities.
Congenital adrenal hyperplasia is the commonest cause of 46,XX
DSD with ambiguous genitalia in the neonatal period or early
infancy and is characterized by androgen excess and a variable
alteration in glucocorticoid and mineralocorticoid function and a
specific profile of steroid hormones.41,42 This profile can identify
the enzyme defects including deficiency of 21a-hydroxylase (90–
95% of cases), 11b-hydroxylase (4–8% of cases), 3b-hydroxyster-
oid dehydrogenase type 2 (3bHSD2; rare) and P450 oxidoreductase
(unknown prevalence). P450 ORD biochemically manifests as
apparent combined CYP17A1 and CYP21A2 deficiency, sometimes
also resembling CYP19A1 (aromatase) deficiency. Unlike other
forms of CAH, ORD is characterized by increased androgen con-
centrations only during the prenatal and early neonatal period, but
rapidly develop sex hormone deficiency. Further details of these
enzyme defects are outlined in Table 3.
46,XX DSD also includes disorders of gonadal development
including 46,XX ovotesticular DSD and 46,XX testicular DSD.
46,XX ovotesticular DSD commonly presents at birth with ambigu-
ous genitalia and progressive virilization during puberty. In con-
trast, individuals with 46,XX testicular DSD usually have a normal
male phenotype and absent Mu¨llerian structures and are often
diagnosed after karyotype analysis during work-up for infertility.
In 46,XX testicular DSD, about 80–90% of patients will have Y
chromosomal material including a translocated SRY gene, which is
only rarely detected in 46,XX ovotesticular DSD. In other cases of
Table 3. Characteristics of 46, XX disorders of sex development due to androgen excess
Inheritance
and Gene Genitalia
Wolffian
duct
derivatives
Mu¨llerian
duct
derivatives Gonads
Typical signs and
symptoms Hormone profile
21-hydroxylase
def
Autosomal
Recessive,
CYP21A2
Ambiguous Absent Normal Ovary Severe adrenal
insufficiency in
infancy ± salt loss;
moderate to severe
androgenization at birth
Decreased cortisol and/or
mineralocorticoids.
Increased 17-hydroxyprogesterone,
21-deoxycortisol,
androstenedione, testosterone,
and/or plasma renin (activity)
11b-hydroxylase
def
Autosomal
Recessive,
CYP11B1
Ambiguous Absent Normal Ovary Adrenal insufficiency in
infancy; moderate to
severe androgenization
at birth; arterial
hypertension often
developing at different ages
Decreased cortisol, corticosterone,
aldosterone, and/or plasma renin
(activity)
Increased 11-deoxycortisol,
11-deoxycorticosterone,
androstenedione, testosterone
3b-hydroxysteroid
dehydrogenase
II def
Autosomal
Recessive,
HSD3B2
Commonly
clitoromegaly
or mild
virilization,
also normal
Absent Normal Ovary Severe adrenal insufficiency
in infancy ± salt loss,
androgenization during
childhood and puberty,
premature pubarche
Increased concentrations of
D5 C21- and C19- steroids,
17 hydroxypregnenolone and
DHEA suppressible by
dexamethasone
P450
oxidoreductase
def
Autosomal
Recessive,
POR
Ambiguous or
normal female
Absent Normal Ovary Variable androgenization at
birth and puberty,
glucocorticoid deficiency,
features of skeletal
malformations.
Maternal androgenization
during pregnancy onset
second trimester possible
Combined P450c17 and P450c21
insufficient, normal or low
cortisol with poor response to
ACTH stimulation, elevated
17-hydroxyprogesterone,
testosterone, progesterone and
corticosterone; low oestradiol.
P450 aromatase
def
Autosomal
Recessive,
CYP19A1
Ambiguous Absent Normal Ovary Delayed bone age,
development of ovarian
cysts during infancy,
childhood and puberty.
Maternal androgenization
during pregnancy
High androgens in cord blood,
androgens may stay elevated or
normalize soon after birth
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46,XX testicular DSD, duplication or upregulation of the SOX9 or
SOX3 gene and mutations of the RSPO1 gene have been described.
In those with a suspicion of 46,XX ovotesticular DSD, functional
testing will require detection of testicular and ovarian tissue by a
combination of biochemical testing, imaging and surgical explora-
tion.
Disorders of Mu¨llerian development are another group of 46,XX
DSD, and in these cases, ovarian function is usually normal but
often associated with cloacal anomalies and other characteristic
malformations. Although most cases of Mu¨llerian development
disorders are not associated with androgen excess, the presence of
the latter, particularly in the adolescent, should alert the clinician
to a possible abnormality of the WNT4 gene.
XY DSDwith low testosterone and low precursors
The differential diagnosis of 46,XY DSD associated with low testos-
terone and low precursors includes the following: high defects in
steroid synthesis (steroidogenic acute regulatory (StAR) protein,
P450side chain cleavage(scc) enzyme/CYP11A1, sometimes Smith-
Lemli-Optiz/DHCR7); LH receptor defects (LHCGR); and partial
and complete forms of gonadal (testicular) dysgenesis (Table 4).
Of note, complete or partial combined 17a-hydroxylase/17,20-
lyase deficiency (CYP17A1) may also present with ‘low testosterone
and low precursors’ if DHEAS and androstenedione are the only
intermediates measured. The actual diagnosis can be reached by
assessment of adrenal function by measuring ACTH, ACTH-stim-
ulated cortisol, PRA, DOC, corticosterone, aldosterone, measure-
ment of D5 (pregnenolone, 17OHPreg) and D4 (progesterone,
17OHP) precursors or urine steroid analysis. Isolated 17,20-lyase
deficiency and ORD might also be diagnosed by this approach.
Proximal blocks (StAR, P450scc) in the pathway affect steroidogen-
esis in the adrenal gland as well as the developing gonad.
Luteinizing hormone receptor defects (‘Leydig cell hypoplasia’)
typically result in elevated basal LH, hyperresponsive LH to GnRH
stimulation, low precursors and testosterone, and impaired andro-
gen response to hCG stimulation. No Mu¨llerian structures will be
present and adrenal function is normal. A spectrum of phenotypes
has been reported including ambiguous genitalia and micropenis.
In some cases, basal LH may not be elevated at times when the
HPG axis is quiescent (6 months to late childhood).
In complete gonadal dysgenesis (‘Swyer syndrome’), affected
people will usually have a female phenotype with intra-abdominal
streak gonads. In some situations, ovotestes or even undifferenti-
ated gonadal tissue may be found.43–45 Mu¨llerian structures are
usually present because of impaired AMH secretion in early foetal
life. Androgens and their precursors will be low, LH elevated,
depending on age, and a poor or absent testosterone response to
hCG stimulation is seen. AMH concentrations will be low or unde-
tectable and adrenal function is usually normal unless the underly-
ing defect is in steroidogenic factor-1 (SF-1) or related adrenal or
gonadal factors.
Partial gonadal (testicular) dysgenesis can present with a spec-
trum of phenotypes ranging from clitoromegaly, to ambiguous
genitalia or severe hypospadias. Mu¨llerian structures may or may
not be present, and testes of variable size and architecture are pres-
ent along the path of descent. The biochemical profile is similar to
complete gonadal dysgenesis, but generally less severe. If mild
degrees of clitoromegaly in infancy are overlooked, a 46,XY child
with partial gonadal dysgenesis may first present at puberty with
progressive androgenization. Genetic analysis and associated fea-
tures may be useful in defining the molecular aetiology of some
forms of gonadal dysgenesis.46
XY DSDwith low testosterone and high steroid
precursors
46,XY DSD with low testosterone and increased precursors can be
caused by several variants of CAH, namely by 17a-hydroxylase
(CYP17A1) deficiency, ORD and 3bHSD2 deficiency, caused by
inactivating mutations in the corresponding genes CYP17A1, POR
and HSD3B2, respectively. In addition, 46,XY DSD with low testos-
terone and increased precursors can typically be found in individu-
als affected by 17bHSD3 deficiency, caused by HSD17B3 mutations
(Table 4).
Deficiency of CYP17A1 leads to CAH in about 1% of cases of
46,XY DSD. Characteristically, affected individuals present with
female genitalia and low DHEA, androstenedione and testosterone.
There is an increase in mineralocorticoid synthesis, and although
there may be cortisol deficiency, this is rarely manifested, as corti-
costerone can also bind and activate the glucocorticoid receptor. In
ORD, sex steroids are characteristically low, sometimes low nor-
mal, whilst pregnenolone and progesterone and their metabolites
accumulate, as expression of the combined block of CYP21A2 and
CYP17A1 activities. Although there is often a relative preponder-
ance of mineralocorticoid over glucocorticoid metabolites in
affected cases, hypertension only manifests in adolescence or later.
Although baseline glucocorticoid secretion is usually sufficient, in
the majority of cases, the stress response to ACTH is significantly
impaired, requiring at least stress dose hydrocortisone cover or per-
manent glucocorticoid replacement. 3b-HSD2 (also termed D4-D5
isomerase) deficiency invariably leads to glucocorticoid deficiency
and as well as a variable degree of mineralocorticoid deficiency and
its characteristic features are outlined in Table 4. 17b-HSD3 defi-
ciency is responsible for the conversion of androstenedione to tes-
tosterone in the gonad and has no effect on adrenal
steroidogenesis. Plasma steroids characteristically show increased
androstenedione levels whilst testosterone levels are concurrently
low, particularly after hCG stimulation. However, a low testoster-
one to androstenedione ratio may also occur in cases of gonadal
dysgenesis and the reliability of a low ratio in identifying 17b-
HSD3 deficiency is unclear. In urine, the typical finding is an
increase in the androgen (and androstenedione) metabolites,
androsterone (An) and etiocholanolone (Et), but it is unclear
whether this applies across all age groups.31
XY DSDwith normal testosterone, normal precursors
and low DHT
The type 2 isoenzyme of 5a-reductase type 2 (SRD5A2) is highly
expressed in androgen-sensitive tissues47 and converts testosterone
to the more potent androgen, DHT, required for the development
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Table 4. Characteristics of 46, XY disorders of sex development
Inheritance
and Gene Genitalia
Wolffian duct
derivatives
Mullerian
duct
derivatives Gonads Typical features Hormone profile
Leydig cell
hypoplasia
Autosomal
Recessive,
LH/HCGR
Female,
hypospadias
or micropenis
Hypoplastic Absent Testes Under androgenization
with variable failure of
sex hormone
production at puberty
Low T and DHT, elevated
LH and FSH, exaggerated
LH response to LHRH, poor
T and DHT response to
hCG stimulation
Lipoid CAH Autosomal
Recessive,
StAR
Female, rarely
ambiguous or
male
Hypoplastic
or normal
Absent Testes Severe adrenal
insufficiency in infancy
with salt loss, failure of
pubertal development,
rare cases associated
with isolated
glucocorticoid
deficiency
Usually deficient of
glucocorticoids,
mineralocorticoids
and sex steroids
P450SCC def Autosomal
Recessive,
CYP11A1
Female, rarely
ambiguous or
hypospadias
Hypoplastic
or normal
Absent Testes Severe adrenal
insufficiency in infancy
with salt loss ranging
to milder adrenal
insufficiency with
onset in childhood
Usually deficient of
glucocorticoids,
mineralocorticoids
and sex steroids
3b-hydroxysteroid
dehydrogenase
II def
Autosomal
Recessive,
HSD3B2
Ambiguous,
hypospadias
Normal Absent Testes Severe adrenal
insufficiency in
infancy ± salt loss,
poor androgenization
at puberty with
gynaecomastia
Increased
concentrations of D5
C21- and
C19- steroids,
17 hydroxypregnenolone
and DHEA suppressible
by dexamethasone
Combined
17a-hydroxylase/
17,20-lyase def
Autosomal
Recessive,
CYP17A1
Female,
ambiguous,
hypospadias
or micropenis
Absent or
hypoplastic
Absent Testes Absent or poor
virilization at puberty,
gynaecomastia,
hypertension
Decreased T, increased LH
and FSH, increased plasma
deoxycorticosterone,
corticosterone and
progesterone, decreased
plasma renin activity, low
renin hypertension with
hypokalaemic alkalosis
Isolated 17,
20-lyase def
Autosomal
Recessive,
CYP17A1,
usually
affecting key
redox
domains,
alternatively
caused by
cytochrome
b5 mutations
(CYB5)
Female,
ambiguous or
hypospadias
Absent or
hypoplastic
Absent Testes Absent or poor
androgenization at
puberty, gynaecomastia
Decreased T, DHEA,
androstenedione and
oestradiol, abnormal increase
in plasma
17-hydroxyprogesterone
and 17-hydroxypregnenolone,
increased LH and FSH,
increased ratio of
C21-deoxysteroids to
C19-steroids after hCG stim
P450
oxidoreductase
def
Autosomal
Recessive,
POR
Ambiguous,
hypospadias or
normal male
Absent or
hypoplastic
Absent Testes Variable androgenization
at birth and puberty,
glucocorticoid
deficiency, features of
skeletal malformations.
Maternal androgenization
during pregnancy onset
second trimester
possible
Combined P450c17 and P450c21
insuff, normal or low cortisol
with poor response to ACTH
stim, elevated
17-hydroxyprogesterone, T low
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of external male genitalia. At birth, the external appearance of the
genitalia of an infant with SRD5A2 deficiency can range from a
completely female phenotype to a range of hypospadias severity or
just isolated micropenis. A positive family history is often present
in this autosomal recessive condition. In serum, the testosterone/
DHT ratio following hCG stimulation usually exceeds 30:1. In
infants over 3–6 months, the defect should be easily identifiable
simply on a urine sample which shows a decreased ratio of 5a:5b-
reduced C21 and C19 steroids and thus can be reached in a child
who had early gonadectomy. Early diagnosis of this condition is
important as the affected infant may need sex reassignment if ini-
tially raised as a girl. In the infant raised as a boy, application of
topical DHT cream may be a method of assessing the potential of
the genitalia to virilize over the longer term.
XY DSDwith normal testosterone, normal precursors
and normal DHT
A defect in androgen signalling is most likely due to dysfunction of
the androgen receptor (AR) and mutations resulting in a complete
lack of function of the AR cause complete androgen insensitivity
syndrome (CAIS).48 This presents in the newborn infant as a dis-
cordance between a female phenotype and a prenatal karyotype of
46,XY, a postnatal check because of a positive family history, or as
inguinal swellings in an otherwise normal girl. CAIS usually pre-
sents in adolescence as primary amenorrhoea with normal breast
development. The presence of pubic hair is often reported in CAIS
and should not be used to exclude the diagnosis. Mutations that
result in some residual AR function and varying degrees of andro-
genization cause PAIS. Although children with AIS typically have
normal testosterone and DHT response to hCG stimulation and a
normal USP, some demonstrate a poor response to hCG stimula-
tion.37,49 The serum AMH concentration is normal or may even be
elevated. LH levels are increased in the face of normal or elevated
serum testosterone, reflecting a state of androgen resistance.36 A
family history of X-linked inheritance is informative although one-
third of cases are the result of spontaneous new mutations.
A functional assessment of androgen sensitivity may include
assessing the clinical effect of a short course of testosterone applied
on the phallus or by the effect of systemic testosterone following
hCG stimulation. However, there is no consensus on the choice of
androgen, dosage, method of administration, timing, duration of
treatment and the definition of a satisfactory response in the
growth of the phallus. Androgen sensitivity can be also assessed by
measuring change in SHBG, an androgen-responsive protein which
normally decreases following androgen exposure. This fall in SHBG
is absent in CAIS, variable in PAIS50 and difficult to interpret in
young infants who have highly variable circulating SHBG. AR
Table 4. (Continued)
Inheritance
and Gene Genitalia
Wolffian duct
derivatives
Mullerian
duct
derivatives Gonads Typical features Hormone profile
17b-hydroxysteroid
dehydrogenase
type 3 def
Autosomal
Recessive
HSD17B3
Female,
ambiguous,
blind vaginal
pouch
Present Absent Testes Androgenisation at
puberty, gynaecomastia
variable
Increased plasma estrone,
decreased ratio of
testosterone/androstenedione
and oestradiol after hCG stim,
increased FSH and LH
5a-reductase-2
def
Autosomal
Recessive
SRD5A2
Ambiguous,
micropenis,
hypospadias,
blind vaginal
pouch
Normal Absent Testes Decreased facial and body
hair, no temporal hair
recession, prostate not
palpable
Decreased ratio of 5a/5b
C21- and C19- steroids in
urine, increased T/DHT ratio
before and after hCG stim,
modest increase in LH,
decreased conversion
of T to DHT in vitro
CAIS X-linked
recessive
AR
Female with blind
vaginal pouch
Often present
depending on
mutation
type
Absent or
vestigial
Testes Scant or absent pubic and
axillary hair, breast
development and female
body habitus at puberty,
primary amenorrhoea
Increased LH and T, increased
oestradiol, FSH levels normal
or slightly increased,
resistance to androgenic and
metabolic effects of T (may be
normal in some cases)
PAIS X-linked
recessive
AR
Ambiguous with
blind vaginal
pouch, isolated
hypospadias,
normal male
with infertility
(mild)
Often normal Absent Testes Decreased to normal
axillary and pubic hair,
beard growth and body
hair, gynaecomastia
common at puberty
Increased LH and T, increased
oestradiol, FSH levels may be
normal or slightly increased,
partial resistance to androgenic
and metabolic effects of T
DHT, dihydrotestosterone; FSH, follicle-stimulating hormone; hCG, human chorionic gonadotrophin; LH, luteinizing hormone; T, testosterone; DHEA,
dehydroepiandrosterone; ACTH, adrenocorticotrophin hormone; AR, androgen receptor; CAIS, complete androgen insensitivity syndrome; PAIS, partial
androgen insensitivity syndrome.
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analysis may reveal a mutation in more than 80% of cases with a
CAIS phenotype and 30% of cases with a PAIS phenotype,51 and
AR binding studies are not necessary for routine diagnosis of AIS.
A number of cases of XY DSD are loosely labelled as ‘PAIS’ when
no conclusive biochemical or genetic abnormalities are identified
in gonadal function, androgen synthesis or androgen action. The
term PAIS should be reserved for those children who have XY DSD
and a pathogenic mutation in AR.
Networks and registers for clinical care, audit and
research
It is unrealistic to expect that every major clinical centre can possess
a comprehensive, multidisciplinary DSD team as outlined earlier.
Furthermore, in many cases, care at a local hospital may be more
appropriate for reasons of both convenience and necessity (for
example, adrenal crisis in CAH). For the less complex case of hypo-
spadias, immediate multidisciplinary input may not be necessary
and initial discussion and explanation of the condition with the par-
ents does not require urgent transfer of the baby at an emotionally
sensitive period. Similarly, some investigations can also be per-
formed at local centres that are affiliated to a regional centre. It is,
however, important that all personnel who may be involved in the
care of an affected person have access to the regional DSD team and
have the opportunity to develop themselves professionally. Some
regions have overcome these hurdles with the development of a
national managed clinical network (http://www.sgan.nhsscot-
land.com). A service model such as this ensures the provision of an
equitable state-of-the-art service for all affected children and adoles-
cents in a region. A formal organization allows a structured referral
pathway within the region as well as beyond and provides the infra-
structure for better long-term care of the patient as close to home as
possible. A network also facilitates the creation of nationally agreed
protocols for the care of the affected newborn, setting and monitor-
ing of national standards of care, and rational utilization of other
services such as clinical genetics and clinical biochemistry and pro-
vides a forum for education and professional development.
Research and audit are vital for the management of DSD, and
clinical networks have a strong potential to drive these activities.
The 2005 Consensus Workshop on DSD stressed the need for the
creation and maintenance of a database in centres of expertise.
Clinical audit systems that collect information on clinical activity
and outcome should be an integral component of national special-
ist services. Such databases may exist at a less formal level in many
other regional centres and until recently have lacked international
uniformity and the ability to crosstalk. A web-based register
(https://tethys.nesc.gla.ac.uk/) has been approved by the UK
National Research Ethics Service as a multicentre research database
which does not require any further local research approvals but
does require the approval of the patient or parent.52 This web-
based register is currently helping the EuroDSD research pro-
gramme and has the potential to address many unanswered ques-
tions about long-term outcome in these rare conditions. Such
registers of patients can also facilitate the development of local cir-
cles of patients and parents with similar conditions who can sup-
port each other.
Conclusion
The rationale for investigating a newborn or an adolescent with a
suspected disorder of sex development may include the need to
determine the sex of rearing, anticipate early medical problems,
explain the aetiology to the young person and the parents of an
affected newborn and, finally, to develop a management plan that
leads to optimal long-term outcome. A rational and empathic
approach that relies on the skills and knowledge of the experts
within the multidisciplinary team is essential for achieving these
goals. An unequivocal diagnosis confirmed by biochemical and
genetic means remains elusive in many cases of disorders of sex
development, particularly XY disorders of sex development. The
stepwise approach to reaching the final diagnosis needs to be
explained to parents and the most important goals of the initial
period of assessment should be to support the affected person and
the parents, assign a sex of rearing and exclude the possibility of
any early medical problems.
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